Prognostic markers in bladder cancer

A contemporary review of the literature

John P. Stein, Gary D. Grossfeld, David A. Ginsberg, David Esrig, John A. Freeman, Arsenio J. Figueroa, Donald G. Skinner, Richard J Cote

Research output: Contribution to journalArticle

251 Citations (Scopus)

Abstract

Purpose: We provide a contemporary review of bladder tumor markers and summarize their role as prognostic indicators. Materials and Methods: A comprehensive review of the literature on prognostic markers for transitional cell carcinoma of the bladder was performed. Results: Intense research efforts are being made to identify and characterize better various bladder cancers and their true biological potential. The need to predict which superficial tumors will recur or progress and which invasive tumors will metastasize has led to the identification of a variety of potential prognostic markers. Blood group antigens, tumor associated antigens, proliferating antigens, oncogenes, peptide growth factors and their receptors, cell adhesion molecules, tumor angiogenesis and angiogenesis inhibitors, and cell cycle regulatory proteins have recently been identified. The potential clinical applications of these tumor markers are under active investigation. Recent attention has focused on which tumor markers may predict the responsiveness of a particular bladder cancer to systemic chemotherapy. Conclusions: At present conventional histopathological evaluation of bladder cancer (tumor grade and stage) cannot predict accurately the behavior of most bladder tumors. With a better understanding of the cell cycle, and cell to cell and cell to extracellular matrix interactions as well as improved diagnostic techniques (immunohistochemistry), progress is being made to identify and characterize other potential prognostic markers for transitional cell carcinoma of the bladder. The ultimate goal is to develop reliable prognostic markers that will accurately predict not only the course but also the response of a tumor to therapy. This information may then be used to dictate more aggressive treatment for tumors that are likely to progress and less aggressive treatment for those that are unlikely to progress. In the future these biological markers may also be used in gene therapy for the treatment of bladder cancer.

Original languageEnglish
Pages (from-to)645-659
Number of pages15
JournalJournal of Urology
Volume160
Issue number3 I
DOIs
StatePublished - Sep 1 1998
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Tumor Biomarkers
Transitional Cell Carcinoma
Neoplasms
Urinary Bladder
Cell Cycle Proteins
Angiogenesis Inhibitors
Growth Factor Receptors
Cell Adhesion Molecules
Neoplasm Antigens
Therapeutics
Blood Group Antigens
Oncogenes
Genetic Therapy
Extracellular Matrix
Cell Cycle
Biomarkers
Immunohistochemistry
Antigens
Drug Therapy

Keywords

  • Biological
  • Bladder neoplasms
  • Carcinoma
  • Transitional cell
  • Tumor markers

ASJC Scopus subject areas

  • Urology

Cite this

Stein, J. P., Grossfeld, G. D., Ginsberg, D. A., Esrig, D., Freeman, J. A., Figueroa, A. J., ... Cote, R. J. (1998). Prognostic markers in bladder cancer: A contemporary review of the literature. Journal of Urology, 160(3 I), 645-659. https://doi.org/10.1016/S0022-5347(01)62747-2

Prognostic markers in bladder cancer : A contemporary review of the literature. / Stein, John P.; Grossfeld, Gary D.; Ginsberg, David A.; Esrig, David; Freeman, John A.; Figueroa, Arsenio J.; Skinner, Donald G.; Cote, Richard J.

In: Journal of Urology, Vol. 160, No. 3 I, 01.09.1998, p. 645-659.

Research output: Contribution to journalArticle

Stein, JP, Grossfeld, GD, Ginsberg, DA, Esrig, D, Freeman, JA, Figueroa, AJ, Skinner, DG & Cote, RJ 1998, 'Prognostic markers in bladder cancer: A contemporary review of the literature', Journal of Urology, vol. 160, no. 3 I, pp. 645-659. https://doi.org/10.1016/S0022-5347(01)62747-2
Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ et al. Prognostic markers in bladder cancer: A contemporary review of the literature. Journal of Urology. 1998 Sep 1;160(3 I):645-659. https://doi.org/10.1016/S0022-5347(01)62747-2
Stein, John P. ; Grossfeld, Gary D. ; Ginsberg, David A. ; Esrig, David ; Freeman, John A. ; Figueroa, Arsenio J. ; Skinner, Donald G. ; Cote, Richard J. / Prognostic markers in bladder cancer : A contemporary review of the literature. In: Journal of Urology. 1998 ; Vol. 160, No. 3 I. pp. 645-659.
@article{0432fbe6aff84991ac2e89dff64d736b,
title = "Prognostic markers in bladder cancer: A contemporary review of the literature",
abstract = "Purpose: We provide a contemporary review of bladder tumor markers and summarize their role as prognostic indicators. Materials and Methods: A comprehensive review of the literature on prognostic markers for transitional cell carcinoma of the bladder was performed. Results: Intense research efforts are being made to identify and characterize better various bladder cancers and their true biological potential. The need to predict which superficial tumors will recur or progress and which invasive tumors will metastasize has led to the identification of a variety of potential prognostic markers. Blood group antigens, tumor associated antigens, proliferating antigens, oncogenes, peptide growth factors and their receptors, cell adhesion molecules, tumor angiogenesis and angiogenesis inhibitors, and cell cycle regulatory proteins have recently been identified. The potential clinical applications of these tumor markers are under active investigation. Recent attention has focused on which tumor markers may predict the responsiveness of a particular bladder cancer to systemic chemotherapy. Conclusions: At present conventional histopathological evaluation of bladder cancer (tumor grade and stage) cannot predict accurately the behavior of most bladder tumors. With a better understanding of the cell cycle, and cell to cell and cell to extracellular matrix interactions as well as improved diagnostic techniques (immunohistochemistry), progress is being made to identify and characterize other potential prognostic markers for transitional cell carcinoma of the bladder. The ultimate goal is to develop reliable prognostic markers that will accurately predict not only the course but also the response of a tumor to therapy. This information may then be used to dictate more aggressive treatment for tumors that are likely to progress and less aggressive treatment for those that are unlikely to progress. In the future these biological markers may also be used in gene therapy for the treatment of bladder cancer.",
keywords = "Biological, Bladder neoplasms, Carcinoma, Transitional cell, Tumor markers",
author = "Stein, {John P.} and Grossfeld, {Gary D.} and Ginsberg, {David A.} and David Esrig and Freeman, {John A.} and Figueroa, {Arsenio J.} and Skinner, {Donald G.} and Cote, {Richard J}",
year = "1998",
month = "9",
day = "1",
doi = "10.1016/S0022-5347(01)62747-2",
language = "English",
volume = "160",
pages = "645--659",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3 I",

}

TY - JOUR

T1 - Prognostic markers in bladder cancer

T2 - A contemporary review of the literature

AU - Stein, John P.

AU - Grossfeld, Gary D.

AU - Ginsberg, David A.

AU - Esrig, David

AU - Freeman, John A.

AU - Figueroa, Arsenio J.

AU - Skinner, Donald G.

AU - Cote, Richard J

PY - 1998/9/1

Y1 - 1998/9/1

N2 - Purpose: We provide a contemporary review of bladder tumor markers and summarize their role as prognostic indicators. Materials and Methods: A comprehensive review of the literature on prognostic markers for transitional cell carcinoma of the bladder was performed. Results: Intense research efforts are being made to identify and characterize better various bladder cancers and their true biological potential. The need to predict which superficial tumors will recur or progress and which invasive tumors will metastasize has led to the identification of a variety of potential prognostic markers. Blood group antigens, tumor associated antigens, proliferating antigens, oncogenes, peptide growth factors and their receptors, cell adhesion molecules, tumor angiogenesis and angiogenesis inhibitors, and cell cycle regulatory proteins have recently been identified. The potential clinical applications of these tumor markers are under active investigation. Recent attention has focused on which tumor markers may predict the responsiveness of a particular bladder cancer to systemic chemotherapy. Conclusions: At present conventional histopathological evaluation of bladder cancer (tumor grade and stage) cannot predict accurately the behavior of most bladder tumors. With a better understanding of the cell cycle, and cell to cell and cell to extracellular matrix interactions as well as improved diagnostic techniques (immunohistochemistry), progress is being made to identify and characterize other potential prognostic markers for transitional cell carcinoma of the bladder. The ultimate goal is to develop reliable prognostic markers that will accurately predict not only the course but also the response of a tumor to therapy. This information may then be used to dictate more aggressive treatment for tumors that are likely to progress and less aggressive treatment for those that are unlikely to progress. In the future these biological markers may also be used in gene therapy for the treatment of bladder cancer.

AB - Purpose: We provide a contemporary review of bladder tumor markers and summarize their role as prognostic indicators. Materials and Methods: A comprehensive review of the literature on prognostic markers for transitional cell carcinoma of the bladder was performed. Results: Intense research efforts are being made to identify and characterize better various bladder cancers and their true biological potential. The need to predict which superficial tumors will recur or progress and which invasive tumors will metastasize has led to the identification of a variety of potential prognostic markers. Blood group antigens, tumor associated antigens, proliferating antigens, oncogenes, peptide growth factors and their receptors, cell adhesion molecules, tumor angiogenesis and angiogenesis inhibitors, and cell cycle regulatory proteins have recently been identified. The potential clinical applications of these tumor markers are under active investigation. Recent attention has focused on which tumor markers may predict the responsiveness of a particular bladder cancer to systemic chemotherapy. Conclusions: At present conventional histopathological evaluation of bladder cancer (tumor grade and stage) cannot predict accurately the behavior of most bladder tumors. With a better understanding of the cell cycle, and cell to cell and cell to extracellular matrix interactions as well as improved diagnostic techniques (immunohistochemistry), progress is being made to identify and characterize other potential prognostic markers for transitional cell carcinoma of the bladder. The ultimate goal is to develop reliable prognostic markers that will accurately predict not only the course but also the response of a tumor to therapy. This information may then be used to dictate more aggressive treatment for tumors that are likely to progress and less aggressive treatment for those that are unlikely to progress. In the future these biological markers may also be used in gene therapy for the treatment of bladder cancer.

KW - Biological

KW - Bladder neoplasms

KW - Carcinoma

KW - Transitional cell

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0032324353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032324353&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)62747-2

DO - 10.1016/S0022-5347(01)62747-2

M3 - Article

VL - 160

SP - 645

EP - 659

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3 I

ER -